UK

The Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory authority responsible for overseeing the safety, quality, and efficacy of medicines, medical devices, diagnostics, and digital health technologies in the United Kingdom. Since the UK's departure from the European Union, the MHRA operates under a fully independent national framework governed by the Human Medicines Regulations 2012 (as amended), the Medical Devices Regulations 2002 (as amended by the Medical Devices (Amendment) (Great Britain) Regulations 2023), and the Medicines Act 1968 for legacy provisions. Products may be approved through the national licensing route, the International Recognition Procedure (IRP), or the new Innovative Licensing and Access Pathway (ILAP), which is designed to accelerate access for promising therapies. Northern Ireland retains a distinct regulatory position under the Windsor Framework, maintaining alignment with certain EU Medical Device Regulations and In Vitro Diagnostic Regulations for products placed on the Northern Ireland market.

Applicants seeking market authorisation in Great Britain must submit dossiers in the Common Technical Document (CTD) format for pharmaceuticals, while medical device manufacturers are required to obtain a UK Conformity Assessed (UKCA) mark, replacing the previously accepted CE mark for the GB market (with transitional arrangements in place through phased deadlines). A UK Responsible Person or UK Establishment is mandatory for all overseas manufacturers. The MHRA has introduced several notable reforms in recent years, including the recognition of approvals from reference agencies such as the US FDA, European EMA, Health Canada, the Therapeutic Goods Administration (TGA), and others under the International Recognition Procedure, substantially reducing duplication of effort. The MHRA's Software and AI as a Medical Device (SaMD/AIaMD) guidance framework and the Digital Technology Assessment Criteria (DTAC) are increasingly relevant for digital health and AI-driven diagnostic products entering the UK market.

Public procurement of health products in the UK is primarily coordinated at the national level through NHS England, which commissions specialised services and sets clinical commissioning policies, and through NHS Supply Chain, the centralised procurement body responsible for sourcing medical devices, diagnostics, consumables, and equipment for NHS trusts across England. Procurement is governed by the Health Care Services (Provider Selection Regime) Regulations 2023 and the Procurement Act 2023, which replaced the Public Contracts Regulations 2015 and introduced a more flexible, outcomes-focused framework. Integrated Care Boards (ICBs), established under the Health and Social Care Act 2022, hold devolved budgets and commissioning responsibilities at the regional level in England, while NHS Scotland (through National Services Scotland and NHS National Procurement), NHS Wales (through NHS Wales Shared Services Partnership), and the Health and Social Care Board in Northern Ireland manage procurement independently within their respective devolved administrations. The National Institute for Health and Care Excellence (NICE) plays a critical gatekeeping role by issuing technology appraisals, medical technology guidance, and diagnostics guidance that directly influence NHS adoption and reimbursement decisions.

The private healthcare sector in the UK, represented by providers such as Bupa, Nuffield Health, and HCA Healthcare UK, procures products through independent contracting processes and is not bound by NHS procurement frameworks, offering an alternative commercial channel for manufacturers. Pharmacy chains, including Boots and LloydsPharmacy, also represent significant procurement channels for over-the-counter diagnostics and consumer health products. The UK does not rely substantially on donor-funded procurement mechanisms such as UNICEF Supply Division, the Global Fund, or USAID for domestic health product access; however, UK-based manufacturers and suppliers may engage with these channels for export and global health programmes, historically supported through UK Aid and the Foreign, Commonwealth and Development Office (FCDO). There are currently no formal domestic local manufacturing preference policies mandating sourcing from UK-based producers, though the government's Life Sciences Vision and the NHS Commercial Framework encourage strategic supply chain resilience and domestic manufacturing investment, particularly following supply disruptions experienced during the COVID-19 pandemic.